These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 542935)
1. Spectrophotometric assays of prothrombin in plasma of patients using oral anticoagulants. Bertina RM; van der Marel-van Nieuwkoop W; Loeliger EA Thromb Haemost; 1979 Dec; 42(4):1296-305. PubMed ID: 542935 [TBL] [Abstract][Full Text] [Related]
2. The inhibitor of prothrombin conversion in plasma of patients on oral anticoagulant treatment. Bertina RM; Westhoek-Kuipers ME; Alderkamp GH Thromb Haemost; 1981 Jun; 45(3):237-41. PubMed ID: 7281102 [TBL] [Abstract][Full Text] [Related]
3. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment. D'Angelo A; Della Valle P; Crippa L; Fattorini A; Pattarini E; Viganò D'Angelo S Haematologica; 2002 Oct; 87(10):1074-80. PubMed ID: 12368163 [TBL] [Abstract][Full Text] [Related]
4. Des-gamma-carboxyprothrombin (PIVKA II) and plasma vitamin K1 in newborns and their mothers. von Kries R; Shearer MJ; Widdershoven J; Motohara K; Umbach G; Göbel U Thromb Haemost; 1992 Oct; 68(4):383-7. PubMed ID: 1448768 [TBL] [Abstract][Full Text] [Related]
5. Levels of acarboxy prothrombin (PIVKA-II) and coagulation factors in warfarin-treated patients. Umeki S; Umeki Y Med Lab Sci; 1990 Apr; 47(2):103-7. PubMed ID: 2381266 [TBL] [Abstract][Full Text] [Related]
6. Prevention of subclinical vitamin K deficiency based on PIVKA-II levels: oral versus intramuscular route. Bakhshi S; Deorari AK; Roy S; Paul VK; Singh M Indian Pediatr; 1996 Dec; 33(12):1040-3. PubMed ID: 9141807 [No Abstract] [Full Text] [Related]
7. Interference of lupus anticoagulants in prothrombin time assays: implications for selection of adequate methods to optimize the management of thrombosis in the antiphospholipid-antibody syndrome. Della Valle P; Crippa L; Garlando AM; Pattarini E; Safa O; Viganò D'Angelo S; D'Angelo A Haematologica; 1999 Dec; 84(12):1065-74. PubMed ID: 10586206 [TBL] [Abstract][Full Text] [Related]
8. [Influence of the protein induced by vitamin K absence on thrombotest and hepaplastintest in the patients treated with oral anticoagulant]. Murakami S; Muratani H; Kikuchi T; Fujimoto S; Hayashi T; Inai S; Imaoka S Rinsho Byori; 1983 Jan; 31(1):105-9. PubMed ID: 6865023 [No Abstract] [Full Text] [Related]
9. Effect of oral water soluble vitamin K on PIVKA-II levels in newborns. Sharma RK; Marwaha N; Kumar P; Narang A Indian Pediatr; 1995 Aug; 32(8):863-7. PubMed ID: 8635828 [TBL] [Abstract][Full Text] [Related]
11. Biological properties of the thromboplastins and plasmas included in the ICTH/ICSH collaborative study on prothrombin time standardization. Loeliger EA; van Halem-Visser LP Thromb Haemost; 1979 Dec; 42(4):1115-27. PubMed ID: 542924 [No Abstract] [Full Text] [Related]
12. Evidence of vitamin K deficiency in cord blood. Mahasandana C; Pung-amritt P; Yodthong S; Suvatte V Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():116-20. PubMed ID: 7886551 [TBL] [Abstract][Full Text] [Related]
13. The "echis carinatus venom" prothrombin assay in coumarin treated patients. A comparison with one-stage and immunological assays. Girolami A; Brunetti A; Patrassi G; Borsato N Folia Haematol Int Mag Klin Morphol Blutforsch; 1976; 103(5):746-57. PubMed ID: 64416 [TBL] [Abstract][Full Text] [Related]
14. Prediction of vitamin K response using the Echis time and Echis-prothrombin time ratio. Solano C; Cobcroft RG; Scott DC Thromb Haemost; 1990 Nov; 64(3):353-7. PubMed ID: 2096486 [TBL] [Abstract][Full Text] [Related]
15. Acarboxy prothrombin (PIVKA-II) in cord plasma in the south of Thailand. Laosombat V; Kenpitak K; Wongchanchailert M; Wiriyasateinkul A J Med Assoc Thai; 1993 May; 76(5):278-84. PubMed ID: 8006559 [TBL] [Abstract][Full Text] [Related]
16. [Evaluation of plasma PIVKA-II as a new marker for hepatocellular carcinoma]. Tada H; Kagawa K; Hikita H; Takeuchi T; Ohta Y; Fukui S; Shintani H; Deguchi T; Okanoue T; Takino T Gan No Rinsho; 1989 Apr; 35(5):564-70. PubMed ID: 2469809 [TBL] [Abstract][Full Text] [Related]
17. [Prothrombin and acarboxyprothrombin activity in neonates after oral and intramuscular administration of vitamin K]. Goldschmidt B; Verbényi M; Kovács I; Ilin E; Varga K; Német T Orv Hetil; 1990 Mar; 131(11):577-82. PubMed ID: 2314877 [TBL] [Abstract][Full Text] [Related]
18. [Clinical usefulness of plasma PIVKA-II assay and its limitations in patients with hepatocellular carcinoma]. Fujiyama S; Morishita T; Shibata J; Sato T Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1129-38. PubMed ID: 2471453 [TBL] [Abstract][Full Text] [Related]
19. Clinical application of a new monoclonal antibody (19B7) against PIVKA-II in the diagnosis of hepatocellular carcinoma and pancreatobiliary malignancies. Nakao A; Taniguchi K; Inoue S; Takeda S; Harada A; Nonami T; Watanabe K; Takagi H Am J Gastroenterol; 1997 Jun; 92(6):1031-4. PubMed ID: 9177525 [TBL] [Abstract][Full Text] [Related]
20. Effects of oral and intramuscular vitamin K prophylaxis on PIVKA-II assay parameters in breastfed infants in Turkey. Uluşahin N; Arsan S; Ertogan F Turk J Pediatr; 1996; 38(3):295-300. PubMed ID: 8827897 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]